Pheochromocytoma with acute heart failure as a complication-emphasis on the etiology of acute heart failure for diagnosis and treatment: a case report
- PMID: 40813639
- PMCID: PMC12355791
- DOI: 10.1186/s12872-025-05044-5
Pheochromocytoma with acute heart failure as a complication-emphasis on the etiology of acute heart failure for diagnosis and treatment: a case report
Abstract
Background: The primary causes of heart failure include myocardial damage and structural abnormalities. In addition to cardiovascular disease, noncardiovascular disease can also lead to heart failure. Identifying these etiologies is critical for accurate diagnosis and timely, targeted treatment.
Case presentation: The patient presented with a 10-month history of recurrent chest tightness and shortness of breath, with symptoms significantly worsening 6 hours before admission. She was diagnosed with acute heart failure in the decompensated phase, complicated by cardiogenic shock. Stabilization was achieved via an intra-aortic balloon pump (IABP) and veno-arterial extracorporeal membrane oxygenation (VA-ECMO). Further evaluation revealed pheochromocytoma as the underlying cause of acute heart failure. The patient underwent successful surgical resection of the pheochromocytoma, with no recurrence of heart failure symptoms observed during follow-up.
Conclusion: Acute heart failure is a rare but critical condition with rapid onset, often presenting as an emergency. Effective management necessitates life support therapy to stabilize the patient, allowing time for further diagnostic and therapeutic measures.
Keywords: Acute heart failure; Case Report; IABP; Pheochromocytoma; VA-ECMO.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The studies involving human participants were reviewed and approved by the Ethics Committee of Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University (College of Integrated Traditional Chinese and Western Medicine Clinical Medicine) (2025–042-JY). Consent for publication: Consent for publication Written informed consent was obtained from the patient for publication of this case report. Competing interests: The authors declare no competing interests.
Figures




Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Extracorporeal membrane oxygenation for critically ill adults.Cochrane Database Syst Rev. 2015 Jan 22;1(1):CD010381. doi: 10.1002/14651858.CD010381.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 Sep 26;9:CD010381. doi: 10.1002/14651858.CD010381.pub3. PMID: 25608845 Free PMC article. Updated.
-
A Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Mechanical Circulatory Support in Acute Myocardial Infarction Related Cardiogenic Shock.Catheter Cardiovasc Interv. 2025 Feb;105(3):650-661. doi: 10.1002/ccd.31369. Epub 2024 Dec 24. Catheter Cardiovasc Interv. 2025. PMID: 39718168
-
Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock.Cochrane Database Syst Rev. 2015 Mar 27;2015(3):CD007398. doi: 10.1002/14651858.CD007398.pub3. Cochrane Database Syst Rev. 2015. PMID: 25812932 Free PMC article.
-
Successful Use of Extracorporeal LVAD for Cardiogenic Shock with Aortic Valve Regurgitation as Bridge to Surgery.Surg Case Rep. 2025;11(1):25-0343. doi: 10.70352/scrj.cr.25-0343. Epub 2025 Jul 26. Surg Case Rep. 2025. PMID: 40746980 Free PMC article.
References
-
- Writing Committee Members, ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022;28(5):e1-e167. 10.1016/j.cardfail.2022.02.010. - PubMed
-
- Petroni T, Harrois A, Amour J, et al. Intra-aortic balloon pump effects on macrocirculation and microcirculation in cardiogenic shock patients supported by venoarterial extracorporeal membrane oxygenation*. Crit Care Med. 2014;42(9):2075–82. 10.1097/CCM.0000000000000410. (PMID: 24810530) - PubMed
-
- Chen Z, Gao Y, Lin Y. Perspectives and considerations of IABP in the era of ECMO for cardiogenic shock. Adv Ther. 2023;40(10):4151–65. 10.1007/s12325-023-02598-8. (Epub 2023 Jul 18 PMID: 37460921). - PubMed
-
- Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2023 Apr 13;108(5):e200. 10.1210/clinem/dgad064]. J Clin Endocrinol Metab. 2014;99(6):1915–42. 10.1210/jc.2014-1498. - PubMed
-
- Zhang R, Gupta D, Albert SG. Pheochromocytoma as a reversible cause of cardiomyopathy: analysis and review of the literature. Int J Cardiol. 2017;15(249):319–23. 10.1016/j.ijcard.2017.07.014. - PubMed
Grants and funding
- LGF22H020018/Zhejiang Provincial Natural Science Foundation of China
- LGF22H020018/Zhejiang Provincial Natural Science Foundation of China
- LGF22H020018/Zhejiang Provincial Natural Science Foundation of China
- No.2022ZA036/Chinese Medical and Health Research Project of Zhejiang Province
- No.2022ZA036/Chinese Medical and Health Research Project of Zhejiang Province
LinkOut - more resources
Full Text Sources